HOUSTON–(BUSINESS WIRE)–SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using Human Dermal Fibroblasts (HDFs), today announced the final results of Phase II Animal Studies for Transplantation of HDFs for Intervertebral Disc Degeneration. Previously reported was significant improvement in disc height. This final report builds on those findings with optimal dosage, biochemistry and biomechanics. The study began in 2014 with Rush University and Howard An, M.D., The Morton International Endowed Chair Professor of Orthopedic Surgery, Director, Division of Spine Surgery and Spine Fellowship Program, Rush University Medical Center. Dr. An’s team is reporting the final results from cell therapy treatment using transplantation of HDFs. When injected with HDFs, the discs were able to significantly increase regeneration, disc height, gene expression of structural genes such as collagen type I and collagen type II, and the contents of structural proteins such as proteoglycan. The study has also proven the spinal disc to be immune privileged. “These results suggests HDFs are a promising option for cell therapy which can restore structure, height and reduce symptoms of degenerated discs,” stated Howard An, M.D.
“This should be considered a landmark scientific breakthrough for a biologic solution to degenerative disc disease,” said Pete O’Heeron, Chief Executive Officer for SpinalCyte. “Dr. An’s team of scientists has provided definitive science that HDFs should be considered a promising option for millions suffering from degenerative disc disease.”
About SpinalCyte, LLC
Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative solution for spinal nucleus replacement using human dermal fibroblasts. To date, SpinalCyte has been funded entirely by angel investors.
Pete O’Heeron, CEO, 281-461-6211